Since TE‐1146 and daratumumab exhibit similar Fc‐mediated immune activities on CD38‐expressing MM cells, its enhanced target cell‐killing activity compared to daratumumab, alone or combined with lenalidomide, can be attributed to its efficient entry into MM cells and subsequent release of cytotoxic lenalidomide. Here, CD38 is linked to Miyoshi myopathy.